Navigation Links
Royalty Pharma Files Judicial Review Proceedings
Date:6/11/2013

NEW YORK, June 11, 2013 /PRNewswire/ -- Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel requiring it to lapse its Further Increased Offer in the event that the ELND005 Transaction and / or the Share Repurchase Program are approved at the Elan (NYSE: ELN) EGM on 17 June 2013.

Royalty Pharma had requested permission from the Irish Takeover Panel to the effect that it would not be obliged to lapse (withdraw) the Offer in the event that the ELND005 Transaction and / or the Share Repurchase Program were approved at the Elan EGM. On 6 June 2013, the Irish Takeover Panel ruled that Royalty Pharma will be required to lapse the Further Increased Offer in the event that either the ELND005 Transaction and / or the Share Repurchase Program are approved at the Elan EGM.

If Elan shareholders approve either the ELND005 Transaction and / or the Share Repurchase Program, Royalty Pharma is concerned that the Irish Takeover Panel's decision will deprive Elan shareholders of the opportunity to consider Royalty Pharma's Further Increased Offer.

IN ORDER TO ENSURE THAT ELAN SHAREHOLDERS HAVE AN OPPORTUNITY TO CONSIDER ROYALTY PHARMA'S FURTHER INCREASED OFFER, ELAN SHAREHOLDERS ARE URGED TO VOTE "AGAINST" ALL FOUR RESOLUTIONS  PROPOSED BY ELAN AT ITS UPCOMING EGM ON 17 JUNE 2013, INCLUDING THE ELND005 TRANSACTION AND THE SHARE REPURCHASE PROGRAM.  

Royalty Pharma will withdraw these judicial review proceedings if Elan shareholders vote down all four resolutions proposed by Elan at its upcoming EGM on 17 June 2013.

Capitalized terms used but not defined in this announcement have the meaning given to them in Royalty Pharma's Further Revised Offer Document.

J.P. Morgan, together with its affiliate J.P. Morgan Cazenove, BofA Merril
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
2. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
3. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
4. Royalty Pharma Acceptances Announcement
5. Royalty Pharma Responds To Elans Tysabri Valuation
6. Royalty Pharma Response To Elans "Categorical View On Value"
7. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
8. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
11. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , ARDEE, Ireland, Nov. 19 Warner ... of its previously announced secondary offering of 20,000,000 of its ... per share. The selling shareholders include funds affiliated with ... by CCMP Capital) and Thomas H. Lee Partners, L.P., certain ...
... , , LYON, France, Nov. 19 ... dangerous and illegal medicines, Operation Pangea II, involving 24 ... Organization,s International Medical Products Anti-Counterfeiting Taskforce (IMPACT) to highlight ... long global initiative resulted in a series of arrests ...
Cached Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... today called for mass screening to identify people prone to ... stroke prevention policy. // ,On the eve of ... myths about strokes -- widely and wrongly believed to be ... ,"Unlike heart attacks, people know very little about strokes. It ...
... health care services provided to children with special health ... to be below their required need. //In addition, the ... their mental health care needs met. These are the ... by Harvard School of Public Health (HSPH) researchers, published ...
... were been faced by the doctors – a report from ... the BMA in Northern Ireland, say a similar case of ... A postal questionnaire addressed to all BMA workers in the ... ,More than half doctors participated in the survey revealed their ...
... Papilloma virus is a major cause of uterine cancer. According ... 70 % of Brazil’s uterine cancer cases//. Hence the Brazilian ... HPV. After the positive test results then the government plans ... are planning to conduct a campaign to vaccinate Brazilian women ...
... being organized to increase awareness of the effects of alcohol ... of drinking// are being highlighted as part of drug action ... alcohol spectrum disorders that cause physical and mental disabilities in ... the incidence of fetal alcohol spectrum disorders in Kimberley is ...
... Health had reported on Thursday that a second Dutch person ... disease, last year a woman died from the disease. ... not however disclose any further details about the patient to ... that eating contaminated meat products would have on all probabilities ...
Cached Medicine News:Health News:Health Care For Children With Special Needs Compromised 2Health News:Drug Action Week to Highlight Effects of Alcohol 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: